IMUC: A recent financing deal brought shares of Immunocellular Therapeutics (IMUC) crashing down towards a dollar earlier this year, but encouraging pipeline news, high volume and new institutional interest has quickly revived the share price and the stock closed Wednesday seventy percent higher than is January lows.
A surge in the Dendreon (DNDN) share price has led to a sector-wide rebound, thanks to reinvigorated Provenge sales, and other cancer immunotherapy companies have benefited as a result; Immunocellular, Celldex Therapeutics (CLDX) and Oncothyreon (ONTY), to name a few.
The revived interest in Dendreon may have potential investors of the sector taking a deeper look at earlier-stage cancer immunotherapy companies - such as IMUC - and may like what they see, given the potential for treatments like Immunocellular's ICT-107 to pick up where Provenge left off and usher in the next generation of such treatments. The manufacturing and logistical advantages held by ICT-107 could lead to much more attractive pricing options - and could also stave off the early marketing troubles endured with Provenge, should the treatment make it to market - which leaves significant room for IMUC share price upside, both in a short and long term speculative nature.
It takes many stocks months to recover from financing lows, but IMUC has quickly regained steam and continues to be a stock on the move.
GLTC: GelTech Solutions (OTCQB:GLTC) has been a hot stock to watch over the past week with a volume boost that has also led to a boost in share price. Wednesday's trading returned a 25 % gain on volume that was roughly five times the daily average. In fact, the past two trading days have been two of the top three highest-volumed days of the new year for GLTC, and follows a trend of increasing volume since the close of 2011.
Undoubtedly it's the growth and distribution potential of FireIce that has caused a stir in the share price and it's expected that new distribution and sales are going to be announced throughout 2012. FireIce is GelTech's revolutionary water-enhancing firefighting product that has received various approvals and qualifications from governments around the globe that frees it up for large-scale, national-level distribution.
With a nice share price spike following a volume spurt, GLTC is still a stock on the move and is one to keep an eye on, especially given the ability of this company's lead product to potentially revolutionize the way municipalities - and even nations - combat and prevent local and widespread wildfires.
SIGA: Just a couple of months ago shares of Siga Technologies (SIGA) were trading for under two dollars, but another six percent bump on Wednesday put them above the $3.50 mark for the first time since mid-October.
There's been no relevant news released to support the SIGA spike, but a very heavy short interest could be starting to cover as many speculate that the worst of the bad news is behind Siga and the company is being set up for a rebound.
With a large BARDA award already in the bag, there's reason to believe that the rebound is for real.
Many media outlets have also been releasing positive updates about the SIGA stock, emphasizing insider buys and short interest that are indicative of a turnaround.
SIGA is a stock on the move right now, and there could be more to come. The past two Fridays have realized a couple of nice price spikes to set up the following week, which might be a hint that some are expecting news and don't want to be caught short through the weekend; so it'll be worth watching the wires for news that might lead to some additional gains.
CELH: The share price for Celsius Holdings (OTCPK:CELH) may not be quite on the move, but volume has slowly been on the move with four of the last eight trading days seeing 25,000-plus shares trade hands. This company has had a rough go of it trying to compete with the big players in the beverage industry, but the past few quarters have shown that the Celsius pre-workout, calorie-burning drink (and powder) may have found a niche.
It's often the name of the game that volume spikes precede price spikes (see GLTC above, for example), so believers of that theory could start following shares of CELH as a potential short term mover. For the year, shares have traded between the low and high twenties, but this past week has made CELH a stock with volume on the move.
TTNP: Titan Pharmaceuticals (OTCQB:TTNP) was a stock on the move as recently as a couple of days ago, but a quick reversal on Wednesday will have many believing that the recent move was as much a head fake as other similar spikes over the past year.
Although closing over eight percent lower on Wednesday, and even with this stock's recent history of nonsustaining short term gains, it still may be too soon to take this one off the 'stocks on the move' list.
The silence from Titan over the past couple of months has many smelling a partnership or buyout, and given the advanced stages of Probuphine for opioid addiction and Titan's proprietary ProNeura technology, there may be some merit to that theory.
Still a mover to watch and has traded as the classic 'trader's dream' (buy the dips, sell the spikes) play for the better part of two years now.
Disclosure: Long SIGA, TTNP, CELH, GLTC.